NEW YORK (GenomeWeb) - Veracyte announced after the close of the market Thursday that revenues for its second quarter rose 37 percent year over year on sales of its Afirma gene expression classifier (GEC) tests.

For the three months ended June 30, 2015, the South San Francisco, California-based molecular diagnostics company said that revenues increased 37 percent to $11.9 million from $8.7 million a year ago, missing the average Wall Street expectation of $12.2 million.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.